a-artemether

alpha-Artemether is a Quinghaosu derivative with antifungal and antimalarial activity.

Beta-Artemether-[13C,D3] (Standard) is a reference standard of Beta-Artemether-[13C,D3] intended for quantitative analysis, quality control, and related biochemical research applications.

Alpha-Artemether-[13C,D3] (Standard) is a reference standard of Alpha-Artemether-[13C,D3] intended for quantitative analysis, quality control, and related biochemical research applications.

ART838 is a dimeric pimeloyl urea compound notable for its potent anti-leukemic activity and favorable pharmacological properties. In vitro, ART-838 exhibits submicromolar inhibitory concentrations against all leukemia cell lines, demonstrating anti-leukemic efficacy 88 times greater than artemether. This compound remains in the body for extended periods and works synergistically with other anti-leukemic agents and novel kinase inhibitors to suppress leukemia cell growth. In immunodeficient NOD-SCID-IL2Rgnull (NSG) mice, ART-838 attains a plasma half-life longer than that of artemether, sustaining effective anti-leukemic concentrations for over 8 hours. Intermittent ART-838 treatment notably inhibited the growth of acute leukemia xenografts and primary grafts in NSG mice, surpassing the efficacy of artemether.

Artemether-lumefantrine (Co-artemether) is a combination antimalarial medication derived from Artemisinin. It is effective against malaria caused by P. falciparum.

Lumefantrine-D9 is a deuterated compound of Lumefantrine. Lumefantrine (T3266) has a CAS number of 82186-77-4. Lumefantrine (T3266) is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.